Priority Research Papers:
Systematic drug perturbations on cancer cells reveal diverse exit paths from proliferative state
Metrics: PDF 1915 views | HTML 2260 views | ?
Joseph X. Zhou1,3,*, Zerrin Isik2,4,*, Caide Xiao3, Irit Rubin1, Stuart A. Kauffman1,3, Michael Schroeder4 and Sui Huang1,3
1 Institute for Systems Biology, Seattle WA, USA
2 Computer Engineering Department, Dokuz Eylul University, Izmir, Turkey
3 Institute for Biocomplexity and Informatics, University of Calgary, Alberta, Canada
4 Biotechnology Center, TU Dresden, Dresden, Germany
* These authors have contributed equally to this work
Sui Huang, email:
Keywords: cancer drug screen, cancer cell differentiation, dynamical system, cell state transition, gene regulatory network
Received: October 16, 2015 Accepted: January 24, 2016 Published: February 09, 2016
During a cell state transition, cells travel along trajectories in a gene expression state space. This dynamical systems framework complements the traditional concept of molecular pathways that drive cell phenotype switching. To expose the structure that hinders cancer cells from exiting robust proliferative state, we assessed the perturbation capacity of a drug library and identified 16 non-cytotoxic compounds that stimulate MCF7 breast cancer cells to exit from proliferative state to differentiated state. The transcriptome trajectories triggered by these drugs diverged, then converged. Chemical structures and drug targets of these compounds overlapped minimally. However, a network analysis of targeted pathways identified a core signaling pathway - indicating common stress-response and down-regulation of STAT1 before differentiation. This multi-trajectory analysis explores the cells’ state transition with a multitude of perturbations in combination with traditional pathway analysis, leading to an encompassing picture of the dynamics of a therapeutically desired cell-state switching.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.